ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,550 GBX | +0.58% |
|
+1.08% | +18.40% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.40% | 245B | |
| +55.19% | 801B | |
| +47.26% | 631B | |
| -6.09% | 359B | |
| +21.92% | 337B | |
| +3.64% | 231B | |
| +12.98% | 219B | |
| +10.86% | 171B | |
| -2.78% | 161B | |
| +1.24% | 121B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug
